PREVENTION OF SUPERIMPOSED PREECLAMPSIA WITH LOW-DOSE ASPIRIN : A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/8rre5590Keywords:
Superimposed preeclampsia, aspirin, pregnancyAbstract
Background: Aspirin is currently the most widely prescribed treatment in the prevention of cardiovascular complications. At low doses, aspirin is also widely used to prevent pregnancy-related vascular disorders, such as preeclampsia and intrauterine growth restriction, and maternal disorders like antiphospholipid syndrome. The indications for the use of aspirin during pregnancy are, however, the subject of much controversy.
The aim: This study aims to show prevention of superimposed preeclampsia with low-dose aspirin.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 39 articles, whereas the results of our search on SagePub brought up 106 articles. The results of the search conducted for the last year of 2013 yielded a total 25 articles for PubMed and 50 articles for SagePub. The result from title screening, a total 10 articles for PubMed and 22 articles for SagePub. In the end, we compiled a total of 10 papers. We included five research that met the criteria.
Conclusion: Aspirin initiated at or before 16 weeks of gestation is associated with a greater reduction in the incidence of PE, perinatal death, and other adverse perinatal outcomes as compared to aspirin initiated after 16 weeks of gestation.
References
Atallah A, Lecarpentier E, Goffinet F, Doret-Dion M, Gaucherand P, Tsatsaris V. Aspirin for Prevention of Preeclampsia. Drugs. 2017;77(17):1819–31.
Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2019;2019(10).
Souza E V., Torloni MR, Atallah AN, Dos Santos GMS, Kulay L, Sass N. Aspirin plus calcium supplementation to prevent superimposed preeclampsia: A randomized trial. Brazilian J Med Biol Res. 2014;47(5):419–25.
Xiao Y, Ling Q, Yao M, Gu Y, Lan Y, Liu S, et al. Aspirin 75 mg to prevent preeclampsia in high-risk pregnancies: a retrospective real-world study in China. Eur J Med Res [Internet]. 2023;28(1):1–8. Available from: https://doi.org/10.1186/s40001-023-01024-7
Boelig RC, Wanees M, Zhan T, Berghella V, Roman A. Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk Urban Cohort: A Prospective Cohort Study. Am J Perinatol. 2021;38(6):544–52.
Tolcher MC, Sangi-Haghpeykar H, Mendez-Figueroa H, Aagaard KM. Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race. Am J Obstet Gynecol MFM [Internet]. 2020;2(4):100184. Available from: https://doi.org/10.1016/j.ajogmf.2020.100184
Wang Y, Guo X, Obore N, Ding H, Wu C, Yu H. Aspirin for the prevention of preeclampsia: A systematic review and meta-analysis of randomized controlled studies. Front Cardiovasc Med. 2022;9(November):1–14.
Huai J, Lin L, Juan J, Chen J, Li B, Zhu Y, et al. Preventive effect of aspirin on preeclampsia in high-risk pregnant women with stage 1 hypertension. J Clin Hypertens. 2021;23(5):1060–7.
Chen WY, Sun SF. Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis. Medicine (Baltimore). 2023;102(34):e34620.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
